CONSORT 2025 statement: updated guideline for reporting randomised trials

Sally Hopewell, An-Wen Chan, Gary S Collins, Asbjørn Hróbjartsson, David Moher, Kenneth F Schulz, Ruth Tunn, Rakesh Aggarwal, Michael Berkwits, Jesse A Berlin, Nita Bhandari, Nancy J Butcher, Marion K Campbell, Runcie C W Chidebe, Diana Elbourne, Andrew Farmer, Dean A Fergusson, Robert M Golub, Steven N Goodman, Tammy C Hoffmann, Isabelle Boutron
{"title":"CONSORT 2025 statement: updated guideline for reporting randomised trials","authors":"Sally Hopewell, An-Wen Chan, Gary S Collins, Asbjørn Hróbjartsson, David Moher, Kenneth F Schulz, Ruth Tunn, Rakesh Aggarwal, Michael Berkwits, Jesse A Berlin, Nita Bhandari, Nancy J Butcher, Marion K Campbell, Runcie C W Chidebe, Diana Elbourne, Andrew Farmer, Dean A Fergusson, Robert M Golub, Steven N Goodman, Tammy C Hoffmann, Isabelle Boutron","doi":"10.1016/s0140-6736(25)00672-5","DOIUrl":null,"url":null,"abstract":"Well designed and properly executed randomised trials are considered the most reliable evidence on the benefits of healthcare interventions. However, there is overwhelming evidence that the quality of reporting is not optimal. The CONSORT (Consolidated Standards of Reporting Trials) statement was designed to improve the quality of reporting and provides a minimum set of items to be included in a report of a randomised trial. CONSORT was first published in 1996, then updated in 2001 and 2010. Here, we present the updated CONSORT 2025 statement, which aims to account for recent methodological advancements and feedback from end users. We conducted a scoping review of the literature and developed a project-specific database of empirical and theoretical evidence related to CONSORT, to generate a list of potential changes to the checklist. The list was enriched with recommendations provided by the lead authors of existing CONSORT extensions (Harms, Outcomes, Non-pharmacological Treatment), other related reporting guidelines (TIDieR) and recommendations from other sources (eg, personal communications). The list of potential changes to the checklist was assessed in a large, international, online, three-round Delphi survey involving 317 participants and discussed at a two-day online expert consensus meeting of 30 invited international experts. We have made substantive changes to the CONSORT checklist. We added seven new checklist items, revised three items, deleted one item, and integrated several items from key CONSORT extensions. We also restructured the CONSORT checklist, with a new section on open science. The CONSORT 2025 statement consists of a 30-item checklist of essential items that should be included when reporting the results of a randomised trial and a diagram for documenting the flow of participants through the trial. To facilitate implementation of CONSORT 2025, we have also developed an expanded version of the CONSORT 2025 checklist, with bullet points eliciting critical elements of each item. Authors, editors, reviewers, and other potential users should use CONSORT 2025 when writing and evaluating manuscripts of randomised trials to ensure that trial reports are clear and transparent.","PeriodicalId":22898,"journal":{"name":"The Lancet","volume":"108 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Lancet","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/s0140-6736(25)00672-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Well designed and properly executed randomised trials are considered the most reliable evidence on the benefits of healthcare interventions. However, there is overwhelming evidence that the quality of reporting is not optimal. The CONSORT (Consolidated Standards of Reporting Trials) statement was designed to improve the quality of reporting and provides a minimum set of items to be included in a report of a randomised trial. CONSORT was first published in 1996, then updated in 2001 and 2010. Here, we present the updated CONSORT 2025 statement, which aims to account for recent methodological advancements and feedback from end users. We conducted a scoping review of the literature and developed a project-specific database of empirical and theoretical evidence related to CONSORT, to generate a list of potential changes to the checklist. The list was enriched with recommendations provided by the lead authors of existing CONSORT extensions (Harms, Outcomes, Non-pharmacological Treatment), other related reporting guidelines (TIDieR) and recommendations from other sources (eg, personal communications). The list of potential changes to the checklist was assessed in a large, international, online, three-round Delphi survey involving 317 participants and discussed at a two-day online expert consensus meeting of 30 invited international experts. We have made substantive changes to the CONSORT checklist. We added seven new checklist items, revised three items, deleted one item, and integrated several items from key CONSORT extensions. We also restructured the CONSORT checklist, with a new section on open science. The CONSORT 2025 statement consists of a 30-item checklist of essential items that should be included when reporting the results of a randomised trial and a diagram for documenting the flow of participants through the trial. To facilitate implementation of CONSORT 2025, we have also developed an expanded version of the CONSORT 2025 checklist, with bullet points eliciting critical elements of each item. Authors, editors, reviewers, and other potential users should use CONSORT 2025 when writing and evaluating manuscripts of randomised trials to ensure that trial reports are clear and transparent.
设计合理、执行得当的随机试验被认为是证明医疗保健干预措施益处的最可靠证据。然而,大量证据表明,试验报告的质量并不理想。CONSORT(试验报告综合标准)声明旨在提高报告质量,并规定了随机试验报告中应包含的最低限度项目。CONSORT 于 1996 年首次发布,随后于 2001 年和 2010 年进行了更新。在此,我们将介绍更新后的 CONSORT 2025 声明,该声明旨在反映最新的方法论进展和最终用户的反馈意见。我们对文献进行了范围性回顾,并开发了与 CONSORT 相关的特定项目实证和理论证据数据库,从而生成了一份核对表潜在变更清单。现有 CONSORT 扩展(危害、结果、非药物治疗)、其他相关报告指南(TIDieR)的主要作者提供的建议以及其他来源(如个人交流)的建议丰富了该清单。317名参与者参与的大型国际在线三轮德尔菲调查评估了核对表的潜在改动清单,并在为期两天、由30名受邀国际专家参加的在线专家共识会议上进行了讨论。我们对 CONSORT 核对表进行了实质性修改。我们新增了 7 个核对表项目,修订了 3 个项目,删除了 1 个项目,并整合了 CONSORT 主要扩展项目中的几个项目。我们还调整了 CONSORT 核对表的结构,新增了关于开放科学的部分。CONSORT 2025 声明包括一份包含 30 个项目的核对表,其中列出了报告随机试验结果时应包含的基本项目,以及用于记录试验参与者流程的图表。为便于实施 CONSORT 2025,我们还开发了 CONSORT 2025 核对表的扩展版,其中的要点概括了每个项目的关键要素。作者、编辑、审稿人和其他潜在用户在撰写和评价随机试验稿件时应使用 CONSORT 2025,以确保试验报告清晰透明。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信